Rucaparib Benefit in BRCA+ Prostate Cancer Confirmed

For patients with metastatic castration-resistant prostate cancer with BRCA alterations, rucaparib doubled progression-free survival as compared with docetaxel, abiraterone, or enzalutamide.
Medscape Medical News